Want to see DE:LIK full AI Analyst Report?
Top Page
Limes Schlosskliniken AG
(XETRA:LIK)
Select Model
Select Model
Rating:74Outperform
Price Target:
€650.00
▲(15.04% Upside)
Action:Reiterated
Date:05/15/26
The score is driven primarily by solid financial performance (growth and profitability with a strengthening balance sheet), tempered by uneven free cash flow and margin volatility. Technicals are supportive with an uptrend across moving averages and positive MACD, while valuation is helped by a low P/E.
Positive Factors
Sustained Top-line Growth
Consistent high revenue growth demonstrates durable demand for LIK's private specialist clinic services and supports scaling of operations. Over 2–6 months this underpins capacity expansion, better utilization of fixed costs, and stronger strategic positioning within Germany's private healthcare segment.
Negative Factors
Uneven Free Cash Flow / Cash Conversion
Volatile free cash flow reduces the company's ability to sustainably self-fund capex, pay dividends, or deleverage. Over a multi-month horizon, weak cash conversion raises refinancing and liquidity risk if operating inflows weaken, and constrains strategic flexibility for investments or margin-supporting initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Top-line Growth
Consistent high revenue growth demonstrates durable demand for LIK's private specialist clinic services and supports scaling of operations. Over 2–6 months this underpins capacity expansion, better utilization of fixed costs, and stronger strategic positioning within Germany's private healthcare segment.
Read all positive factors
Limes Schlosskliniken AG (LIK) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€171.00M
Dividend Yield1.74%
Average Volume (3M)37.00
Price to Earnings (P/E)30.1
Beta (1Y)-0.05
Revenue Growth33.49%
EPS Growth81.79%
CountryDE
Employees314
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)19.29
Shares Outstanding300,000
10 Day Avg. Volume27
30 Day Avg. Volume37
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)4.17
Price to Sales (P/S)2.11
P/FCF Ratio142.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31.18
Revenue Forecast (FY)€66.40M
Limes Schlosskliniken AG Business Overview & Revenue Model
Company Description
LIMES Schlosskliniken AG oversees private healthcare facilities specializing in psychiatric, psychotherapeutic, and psychosomatic treatments. The organization primarily concentrates on addressing conditions arising from stress, alongside a variety...
How the Company Makes Money
null...
Limes Schlosskliniken AG Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 50.00M | 37.45M | 37.17M | 28.81M | 23.43M |
| Gross Profit | 19.06M | 34.50M | 16.23M | 10.82M | 8.37M |
| EBITDA | 12.79M | 7.05M | 7.67M | 8.65M | 6.02M |
| Net Income | 5.69M | 3.11M | 3.40M | 4.20M | 3.94M |
Balance Sheet | |||||
| Total Assets | 45.17M | 38.56M | 33.25M | 26.65M | 18.44M |
| Cash, Cash Equivalents and Short-Term Investments | 10.31M | 10.88M | 8.52M | 10.93M | 2.48M |
| Total Debt | 10.73M | 10.48M | 10.09M | 9.04M | 4.33M |
| Total Liabilities | 18.35M | 18.72M | 16.61M | 15.45M | 12.13M |
| Stockholders Equity | 25.31M | 18.33M | 15.13M | 11.10M | 6.31M |
Cash Flow | |||||
| Free Cash Flow | 740.24K | 2.48M | -3.51M | 6.35M | -1.83M |
| Operating Cash Flow | 9.38M | 7.46M | 6.29M | 7.70M | 4.55M |
| Investing Cash Flow | -8.63M | -4.96M | -9.79M | -1.31M | -6.38M |
| Financing Cash Flow | -1.25M | -159.15K | 1.09M | 2.04M | 1.40M |
Limes Schlosskliniken AG Technical Analysis
Positive
565.00
Price Trends
542.00
Positive
512.18
Positive
455.13
Positive
Market Momentum
10.00
Negative
59.67
Neutral
61.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:LIK, the sentiment is Positive. The current price of 565 is above the 20-day moving average (MA) of 562.75, above the 50-day MA of 542.00, and above the 200-day MA of 455.13, indicating a bullish trend. The MACD of 10.00 indicates Negative momentum. The RSI at 59.67 is Neutral, neither overbought nor oversold. The STOCH value of 61.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:LIK.
Limes Schlosskliniken AG Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | €353.76M | 15.33 | 18.60% | 6.83% | 7.40% | 38.17% | |
74 Outperform | €171.00M | 30.07 | 24.05% | 1.79% | 33.49% | 81.79% | |
66 Neutral | €26.10B | 17.33 | 7.89% | 2.40% | 5.30% | 35.29% | |
66 Neutral | €223.25M | 7.73 | 11.54% | 0.94% | 2.94% | -14.28% | |
59 Neutral | €997.38M | 23.44 | 3.04% | 1.55% | 4.91% | 11.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | €19.50M | -1.23 | 21.40% | ― | 3.53% | -5.29% |
* Healthcare Sector Average
DE:LIK
Limes Schlosskliniken AG
580.00
232.74
67.02%
DE:FRE
Fresenius SE & Co. KGaA
46.82
2.00
4.46%
DE:MED
MEDICLIN
4.70
1.65
54.25%
DE:RHK
RHON-KLINIKUM AG
15.00
3.78
33.73%
DE:MAK
MATERNUS-Kliniken AG
0.93
-0.28
-23.14%
DE:M12
M1 Kliniken AG
18.40
5.63
44.08%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.